Enodia Therapeutics acquired Kezar Life Sciences’ Sec61 discovery and development assets, including clinical‑stage candidate KZR‑261, under a deal that includes an initial $1 million upfront payment and up to $127 million in potential milestones. The transactions were disclosed in company statements and trade press coverage. Enodia said the acquisition strengthens its targeted protein degradation approach by adding Kezar’s Sec61 datasets and chemical matter, enabling rational design and machine‑learning‑driven program advancement. Kezar retains potential milestone and royalty upside, per the announced terms. Sec61 translocon modulation is an emerging modality aimed at blocking synthesis of disease‑relevant proteins at the point of translation; the acquisition accelerates Enodia’s ability to design selective degraders and integrate Kezar’s preclinical and clinical learnings into its pipeline.